File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.semnephrol.2018.05.023
- Scopus: eid_2-s2.0-85054049949
- PMID: 30177025
- WOS: WOS:000443239900012
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Treatment of IgA Nephropathy: Evolution Over Half a Century
Title | Treatment of IgA Nephropathy: Evolution Over Half a Century |
---|---|
Authors | |
Keywords | IgA nephropathy Treatment Clinical trial Pathogenesis |
Issue Date | 2018 |
Publisher | WB Saunders Co. The Journal's web site is located at http://www.seminarsinnephrology.org/ |
Citation | Seminars in Nephrology, 2018, v. 38 n. 5, p. 531-540 How to Cite? |
Abstract | Fifty years into the original description of IgA nephropathy, there is still no specific therapy for this condition and general measures including blood pressure control with blockers of the renin-angiotensin-aldosterone system and salt restriction remain the cornerstone to slow disease progression. Although the paucity in treatment advances could be related to the disease's complex pathogenesis, which requires multiple hits, heterogeneity as reflected by diverse ethnic differences, and genetic predisposition and histopathologic variations, many nonspecific and immunomodulatory agents have been tested with variable degrees of success and tribulations. Here, we review the evolution of these different therapeutic approaches over time that culminated in the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Glomerulonephritis that presently is being updated, and provide an appraisal of recent data on various forms of immunosuppressive agents. Finally, we discuss the theoretical basis of ongoing and upcoming clinical trials that are more pathway- or cell-type–specific as knowledge in disease mechanisms advances. |
Persistent Identifier | http://hdl.handle.net/10722/275087 |
ISSN | 2021 Impact Factor: 4.472 2020 SCImago Journal Rankings: 1.623 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Barratt, J | - |
dc.contributor.author | Tang, SCW | - |
dc.date.accessioned | 2019-09-10T02:35:11Z | - |
dc.date.available | 2019-09-10T02:35:11Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Seminars in Nephrology, 2018, v. 38 n. 5, p. 531-540 | - |
dc.identifier.issn | 0270-9295 | - |
dc.identifier.uri | http://hdl.handle.net/10722/275087 | - |
dc.description.abstract | Fifty years into the original description of IgA nephropathy, there is still no specific therapy for this condition and general measures including blood pressure control with blockers of the renin-angiotensin-aldosterone system and salt restriction remain the cornerstone to slow disease progression. Although the paucity in treatment advances could be related to the disease's complex pathogenesis, which requires multiple hits, heterogeneity as reflected by diverse ethnic differences, and genetic predisposition and histopathologic variations, many nonspecific and immunomodulatory agents have been tested with variable degrees of success and tribulations. Here, we review the evolution of these different therapeutic approaches over time that culminated in the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Glomerulonephritis that presently is being updated, and provide an appraisal of recent data on various forms of immunosuppressive agents. Finally, we discuss the theoretical basis of ongoing and upcoming clinical trials that are more pathway- or cell-type–specific as knowledge in disease mechanisms advances. | - |
dc.language | eng | - |
dc.publisher | WB Saunders Co. The Journal's web site is located at http://www.seminarsinnephrology.org/ | - |
dc.relation.ispartof | Seminars in Nephrology | - |
dc.subject | IgA nephropathy | - |
dc.subject | Treatment | - |
dc.subject | Clinical trial | - |
dc.subject | Pathogenesis | - |
dc.title | Treatment of IgA Nephropathy: Evolution Over Half a Century | - |
dc.type | Article | - |
dc.identifier.email | Tang, SCW: scwtang@hku.hk | - |
dc.identifier.authority | Tang, SCW=rp00480 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.semnephrol.2018.05.023 | - |
dc.identifier.pmid | 30177025 | - |
dc.identifier.scopus | eid_2-s2.0-85054049949 | - |
dc.identifier.hkuros | 303439 | - |
dc.identifier.volume | 38 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 531 | - |
dc.identifier.epage | 540 | - |
dc.identifier.isi | WOS:000443239900012 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0270-9295 | - |